- Open Access
Depletion of the histone chaperone tNASP inhibits proliferation and induces apoptosis in prostate cancer PC-3 cells
© Alekseev et al; licensee BioMed Central Ltd. 2011
Received: 14 February 2011
Accepted: 16 April 2011
Published: 16 April 2011
NASP (Nuclear Autoantigenic Sperm Protein) is a histone chaperone that is present in all dividing cells. NASP has two splice variants: tNASP and sNASP. Only cancer, germ, transformed, and embryonic cells have a high level of expression of the tNASP splice variant. We examined the consequences of tNASP depletion for prostate cancer PC-3 cells.
tNASP was depleted from prostate cancer PC-3 cells, cervical cancer HeLa cells, and prostate epithelial PWR-1E cells using lentivirus expression of tNASP shRNA. Cell cycle changes were studied by proliferation assay with CFSE labeling and double thymidine synchronization. Gene expression profiles were detected using RT2Profiler PCR Array, Western and Northern blotting.
PC-3 and HeLa cells showed inhibited proliferation, increased levels of cyclin-dependant kinase inhibitor p21 protein and apoptosis, whereas non-tumorigenic PWR-1E cells did not. All three cell types showed decreased levels of HSPA2. Supporting in vitro experiments demonstrated that tNASP, but not sNASP is required for activation of HSPA2.
Our results demonstrate that PC-3 and HeLa cancer cells require tNASP to maintain high levels of HSPA2 activity and therefore viability, while PWR-1E cells are unaffected by tNASP depletion. These different cellular responses most likely arise from changes in the interaction between tNASP and HSPA2 and disturbed tNASP chaperoning of linker histones. This study has demonstrated that tNASP is critical for the survival of prostate cancer cells and suggests that targeting tNASP expression can lead to a new approach for prostate cancer treatment.
Nuclear Autoantigenic Sperm Protein (NASP) is a histone chaperone that binds both core and linker histones [1–4], with a higher affinity for linker histones than core histones ; NASP is present in all dividing cells. First characterized in rabbit testis  as a homologue to the Xenopus oocyte histone binding protein N1/N2 [7, 8], NASP has been shown to transport linker histones into the nucleus, transferring H1 histones onto DNA and facilitating chromatin assembly . NASP overexpression  as well as NASP depletion induced by siRNA treatment  causes disruption in the cell cycle, changes in gene expression profiles , and in mice the NASP -/- null mutation is embryonic lethal . Transcribed from a single copy gene, NASP has two splice variants: tNASP, which is found in cancer, transformed, embryonic and germ cells and sNASP, which is found in embryonic and somatic cells .
NASP appears to be a multifunctional chaperone protein participating in a variety of regulatory pathways. In developing embryonic stem cells 356 network connectivity episodes have been reported for NASP, suggesting multiple direct protein-protein interactions . During meiosis in the mouse tNASP regulates CDC2/cyclin B1 complex formation through the modulation of HSPA2 ATPase activity ; during nucleosome assembly in both DNA synthesis-dependent and independent pathways CAF1 and HIRA are associated with NASP [3, 14]; and during DNA repair NASP is associated with KU70 .
NASP has been reported as a serologic marker for ovarian cancer, which could be suitable for clinical testing in high-risk populations . Different types of cancer and different stages of the same cancer have been demonstrated to have specific expression profiles for NASP: grade 1 and 2 of breast cancers show up regulation of NASP compared to grade 3 . Estrogen positive tumors express more NASP then estrogen negative ones and similarly sporadic versus BRCA1/BRCA2 mutation positive tumors show different NASP signatures . NASP has become an important constituent of the "poor prognosis signature" in breast cancer patients  and the "aggressive tumor gene signature" in lung cancer patients . Although NASP has been reported to be an important prognostic marker in prostate cancer cells , it is not clear if tNASP has a specific role is this cancer.
NASP expression is characteristic of all dividing cells, but only cancer, germ, embryonic and transformed cells have a high level of expression of the tNASP splice variant. Consequently we asked the question: what characterizes tNASP in rapidly dividing cells? The current study was undertaken to specifically characterize depletion of tNASP in three different cell lines (prostate cancer PC-3 cells; cervical cancer HeLa cells; non-tumorigenic transformed prostate epithelial PWR-1E cells) and the cellular pathways activated as a consequence.
This study has demonstrated that tNASP is critical for the survival of prostate cancer PC-3 cells and suggests that targeting tNASP expression can lead to a new approach for prostate cancer treatment.
All chemicals and reagents used in this study were of molecular biology grade. FuGENE®6 Transfection Reagent was purchased from Roche Applied Science (Indianapolis, IN). QIAprep Miniprep, QIAquick PCR purification kits, RNeasy mini kit, RNase-Free DNase Set, and Effectene® Transfection Reagent were purchased from Qiagen (Valencia, CA). Restriction enzymes and DNA ligase were obtained from NEB (New England Biolabs, Ipswich, MA). Carboxyfluorescein diacetate, succinimidyl ester (CFSE) and thymidine were purchased from Sigma (Saint Louis, MO). RT2 Profiler PCR Array, RT2 First Strand Kit, and RT2 SYBR Green qPCR Master Mix were purchased from SABiosciences Corporation (Frederick, MD). Sequencing was performed at the University of North Carolina at Chapel Hill automated sequencing facility. Mouse monoclonal anti p53 antibody (DO-1) and rabbit polyclonal anti-p21 antibody (SC-397) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit cleaved caspase-3 (Asp175) antibody was a gift from Dr. Mohanish Deshmukh (Department of Cell and Developmental Biology, University of North Carolina at Chapel Hill). Mouse monoclonal antibody to HSPA2 (ab55290) was purchased from Abcam Inc. (Cambridge, MA). Goat antiserum to full-length recombinant human tNASP (AAH10105) was custom made by Bethyl Laboratories (Montgomery, TX). Goat affinity purified specific anti-tNASP antibody was prepared by absorbing the anti-tNASP antiserum with recombinant sNASP until the anti-tNASP antibody did not react with recombinant sNASP on a Western blot.
PC-3, HeLa, and PWR-1E  cells were used in this study. All the cells were obtained directly from the American Type Culture Collection (ATCC, Manassas, VA).
Northern blot analysis
Total RNA samples from cell cultures were purified using RNeasy Mini Kit and blotted to Amersham Hybond-N nylon membrane (GE Healthcare, Little Chalfont, UK). The blots were probed with a 32P-labeled 750 base pair cDNA from the C-terminal of human NASP, which is identical in sequence for both tNASP and sNASP. Hybridization was carried out in QiuckHyb solution (Agilent Technologies, Santa Clara, CA). Radioactive bands were detected in a PhosphorImager Storm-860 (Molecular Dynamics, Piscataway, NJ).
Cells were grown on chamber slides with polystyrene wells (BD Biosciences, Bedford, MA), fixed with chilled methanol (-20°C, 20 min) and incubated in goat affinity purified specific anti-tNASP antiserum or pre-immune serum (1:500 in 0.5% BSA in PBS), or in caspase-3 antibody (1:200) for 1 hour. After the washing in PBS twice, cells were incubated in Alexa Flour® 488 donkey anti-goat IgG (1:4000 in 0.5% BSA in PBS, Molecular Probes, Eugene, OR). Secondary antibody controls were included in all experiments and were negative.
Senescence-associated β-galactosidase staining
PC-3, HeLa, and PWR-1E cells were plated on culture slides (BD Biosciences, Bedford, MA) and treated by tNASP shRNA or scrambled shRNA lentivirus. Four days after treatment cells were stained for senescence-activated β-galactosidase activity at pH 6  using a Senescence β-Galactosidase Staining Kit (Cell Signaling Technology, Danvers, MA) accordingly the manufacturer's instructions.
Double thymidine block
HeLa cells were blocked with thymidine to arrest all the cells at the beginning of S phase . The cells were released by washing out the thymidine, harvested at 0, 4, and 8 hours after release and examined for DNA content by FACS.
Cell proliferation assay
The cell proliferation (cell division) assay was carried out by labeling scrambled and tNASP shRNA treated PC-3, HeLa, and PWR-1E cells with CFSE . A stock solution (5 mM CFSE in DMSO) was prepared and stored at -80°C. Control and experimentally treated cells were trypsinized, washed twice in sterile PBS and re-suspended in 2 ml of sterile PBS, pre-warmed to 37°C. The stock solution of CFSE was used at a final concentration of 5 μM after incubation at 37°C for 10 min in the dark. To quench the labeling, cells were washed twice with DMEM cell culture medium containing penicillin/streptomycin and 10% FBS. Cells were allowed to grow for an additional 3 days. After 72 hours of growth, cells were washed by PBS, trypsinized, washed in PBS, fixed in 70% ethanol for 2 hours, and stained with tNASP specific antiserum. A parental population of cells was obtained by labeling cells followed by their immediate fixation in 70% ethanol.
Fluorescent-activated cell sorting (FACS) analysis
Scrambled and tNASP shRNA treated cells 0, 4, and 8 hours after release from the double thymidine block were washed with PBS, trypsinized, and fixed with 70% ethanol for ≥ 2 h on ice. Cells were immunostained with goat anti-tNASP affinity purified antibody, washed twice in PBS and stained with secondary antibody Alexa Fluor 647 donkey anti-goat IgG (H+L) A21447 (Invitrogen, Eugene, OR). Cells were washed in PBS and stained for 30 min at 37°C with 50 μg/ml propidium iodide in PBS (containing 200 μg/ml RNAse A and 0.1% Triton X-100), and incubated overnight at 4°C before analysis at the University of North Carolina at Chapel Hill Flow Cytometry Facility on a Dako Cyan ADP flow cytometer. For each sample at least 10,000 cells were counted. After gating out doublets and debris, cell cycle distribution was analyzed using Summit version 4.3 software (Dako Colorado, Inc., Fort Collins, CO). For the cell proliferation assay, CFSE labeled cells were fixed in 70% ethanol for at least 2 hours and immunostained with specific anti-tNASP antibodies as described above.
Construction of lentivirus to express shRNA targeting human tNASP
Designing shRNA oligos for pLKO.1
For selection of 21-mer targets within the human t-NASP specific part of the sequence (NM_002482), we used an automated service provided by the Broad Institute . Out of more than 200 possible targets 10 top-scoring targets were selected for further study. Forward and reverse oligos compatible with pLKO.1  were designed and produced in the UNC Oligonucleotide Synthesis Core Facility. Annealing of forward and reverse oligonucleotides was carried out in a PCR machine at 95°C for 4 min, 70°C for 10 min with slow cooling to room temperature over 4 hours. The vector pLKO.1 was sequentially digested by Age1 and EcoR1 restriction enzymes and ligated with annealed oligonucleotides using NEB T4 DNA ligase. The ligated construct was propagated in DH5α cells. Plasmids were purified with a Miniprep kit and successful ligations were verified by a sequencing reaction. Individual tNASP shRNA constructs were screened using Effectene® Transfection Reagent for transient knockdown of tNASP mRNA levels in easy to transfect HeLa cells. The two most active shRNA constructs were selected and used for the production of lentiviral particles.
Both packaging plasmid psPAX2 and envelope plasmid pMD2.G were obtained from Addgene . Lentiviral particles were generated in HEK-293T cells. Plasmids were transfected using FuGENE®6 Transfection Reagent. Target cells were infected by adding lentiviral particles to growth medium. For better transfection polybrene (hexadimethrine bromide, final concentration 8 μg/ml) was added to the culture medium. Infected cells were selected by puromycin pressure added to a final concentration of 3 μg/ml. Negative controls were the mock transfection with Addgene plasmid 1864. The sequence of this shRNA does not have any cellular target .
RT2Profiler PCR Array
RT2 Profiler PCR Array was used as a method of combining real-time PCR performance with a simultaneous analysis of a panel of genes related to the cell cycle (array PAHS-020D. Preparation and analysis of samples were carried out in accordance with the manufacturer's recommendations. Arrays were run on an Opticon 2 thermal cycler (Bio-Rad, Hercules, CA). Threshold cycle values were analyzed using web-based PCR array data analysis software . Reverse transcriptase control, cDNA control, and positive PCR control were within the accepted range.
Colorimetric determination of ATPase activity (Malachite Green Assay)
The amount of inorganic phosphate liberated by HSPA2 in the presence of tNASP or sNASP was determined by a malachite green assay  based on the formation of a phosphomolybdate complex as we previously described for HIST1H1T . Protein concentrations were 0.5 μM for HSPA2, CDC2, tNASP, sNASP and HIST1H1A. Significance was determined by the Student t-test.
Changes in cell number
Affect of tNASP depletion on cell proliferation
Only the tNASP depleted cells were gated in the following FACS experiments and used for the proliferation assay. To determine the position of undivided cells (called the parental population) a portion of the PC-3, HeLa, and PWR-1E cells was labeled with CFSE, a protein stain, after tNASP shRNA treatment and immediately fixed. The CFSE labeling in each group of cells is shown as the parental population in Figure 5B,F, and 5J and marks the position of the original amount of CFSE in each cell line. The experimental and control transfected cells were labeled with CFSE on day 3 after treatment and grown for an additional 3 days. Control HeLa cells (Figure 5C) show three distinct peaks (from arrow, right to left in Figure 5C) representing three cell division cycles with no cells remaining undivided (the amount of CFSE in all 3 peaks is equal to that in the original parent population) and 81% of the cells completed the third division. In contrast 48% of tNASP shRNA treated HeLa cells could not complete the first division (Figure 5D), 34% completed the first division and only 18% could complete the second and third divisions.
Control treated PC-3 cells examined under identical experimental conditions to the HeLa cells completed either one or two divisions by day 3 (Figure 5G): 71% completed two divisions, 28% completed one division, and 1% did not divide. In contrast, proliferation was significantly affected in tNASP shRNA treated cells: 46% completed two divisions, 51% completed only one division, and 3% of cells did not divide (Figure 5H). PWR-1E cells were distinct from both HeLa and PC-3, under identical conditions they completed 2 divisions and there was no difference between experimental and control (scrambled) treated cells (Figure 5K,L). These experiments demonstrate that depletion of tNASP has distinct effects on different cell lines, retarding cell cycle proliferation in PC-3 and HeLa cells but not in PWR-1E cells.
Cell cycle progression
Senescence or apoptosis
We next asked the question: what happens to the tNASP depleted PC-3 and HeLa cells? To determine if the cells undergo senescence we tested for β-galactosidase activity at pH 6, which is a known characteristic of senescent cells . PC-3, HeLa, and PWR-1E tNASP depleted cells did not show any β-galactosidase activity (data not shown). To determine if the cells undergo apoptosis we stained the tNASP depleted cells for active caspase-3, which is a marker for early apoptosis and indicative of cells in the apoptosis pathway [33, 34]. Four days after tNASP shRNA treatment PC-3, HeLa and PWR-1E cells were immunostained with antibody to cleaved caspase-3. As shown in Figure 6B staining reveled that numerous tNASP depleted PC-3 and HeLa cells contained activated caspase-3 (Figure 6B; a-b; c-d). Control treated cells were negative for activated caspase-3 (data not shown). In contrast to PC-3 and HeLa cells, tNASP depleted PWR-1E cells were negative for caspase-3 (Figure 6B; e-f). These data indicate that in PC-3 and HeLa cells the depletion of tNASP induces apoptosis, in contrast to non-tumorigenic PWR-1E cells in which proliferation is unaffected and apoptosis is not induced.
Gene expression profiles
Cell cycle related genes regulated by the depletion of tNASP
Gene Symbol (GenBank)2
Cyclin-dependent kinase inhibitor 1A (p21)
Cyclin-dependent kinase 6
Cyclin-dependent kinase inhibitor 2A (p16)
Cyclin-dependent kinase inhibitor 1A (p21)
CDC28protein kinase regulatory subunit 2
Cyclin-dependent kinase inhibitor 1A (p21)
Cyclin-dependent kinase inhibitor 1B (p27)
Cyclin-dependent kinase 6
B-cell Cell/lymphoma 2
Expression of p21
Expression of p21 was confirmed by Western blots six days after treatment. As shown in Figure 2, p21 is up regulated in PC-3 and HeLa cells but not in PWR-1E cells. The protein p21 is a well established inhibitor of cyclin-CDK2 or cyclin-CDK4 complexes and functions as a regulator of cell cycle progression at G1, consistent with our findings in the cell cycle analysis.
This study has demonstrated that selective depletion of tNASP from PC-3, HeLa and PWR-1E cell lines in culture leaves sNASP unaffected and results in distinctly different effects. Using lentiviral expression of tNASP shRNA, all three cell lines had decreased HSPA2 protein levels, yet only PC-3 and HeLa cells increased expression of p21 and entered apoptosis. NASP has been detected in all dividing cells, but only cancer, transformed, germ, and embryonic cells have a high level of expression of the tNASP splice variant . Depletion of both tNASP and sNASP has been shown to be embryonic lethal and without sufficient NASP HeLa and U2OS cells were unable to enter S phase . However, these studies did not distinguish whether tNASP and sNASP played separate roles and raised the question why rapidly dividing cells such as cancer or embryonic cells expressed tNASP while adult somatic cells did not.
The results reported in this study clearly demonstrated that in prostate cancer PC-3 cells and cervical cancer HeLa cells depletion of tNASP caused significant anti-proliferative effects and induced apoptosis while the non-tumorigenic prostate epithelial PWR-1E cells did not experience these changes in the time span observed. Cells depleted of tNASP slowed down their proliferation and were blocked at the G1/S border of the cell cycle, which is consistent with our earlier report .
The activation of p53 could result in apoptosis, cell-cycle arrest, DNA repair or senescence [38, 39]; however activation of p53 is not relevant in our study because we used cell lines with non-functional, inhibited or mutated p53. HeLa cells, which originate from adenocarcinoma of the cervix, contain wild-type p53 alleles together with the DNA of specific types of human papillomaviruses  and the transcriptional stimulatory activity of HeLa cell p53 is strongly repressed by one of the oncogenic papilomavirus products, E6 protein . In PC-3 prostate cancer cells p53 is absent due to deletion of a base pair in the single copy gene and that generates a frame shift and a new immediate stop codon [42, 43]. PWR-1E cells were immortalized by adenovirus 12-SV40 and although they show strong nuclear staining for p53  its activity is inhibited by the binding between p53 and SV40 Large T-antigen . In this study p53 protein could only be detected on Western blots in PWR-1E cells (Figure 2).
The up regulation of p21 appears to be important in the cell lines we studied. Expression of p21 mRNA increased in all three cell lines; however protein levels were increased only in PC-3 and HeLa cells. p21 is known to be a potent cell cycle progression inhibitor because it inhibits the activity of cyclin-dependant kinase-cyclins A, D, and E complexes . Although it is well established that p21 mediates p53-dependant G1/S phase growth arrest in response to DNA damage [46, 47], p21 expression could be induced by mechanisms independent of p53. In this case the expression of p21 is up regulated by different transcription factors: E2F1 through the activation of Ras , SP1, SP3, AP2, HOXA10, STAT , AP-1 .
Because tNASP is a chaperone for linker histones and transports them into the nucleus in an energy and nuclear localization signal-dependent manner , the depletion of tNASP implies that there could be a simultaneous depletion of H1 histones in the nucleus. Depletion of linker histones has been reported to be sufficient for altering the expression of subsets of genes, the up regulation of p21 in particular, and for G1-phase cell cycle arrest in human breast cancer cells . Regulation of DNA replication through multiple pathways in egg extracts has been reported to be dependent on sufficient linker histones . Decreased levels of H1 histones down to 50% from their normal level caused profound chromatin structural changes, including global nucleosome spacing, reduced chromatin compaction, and decreases in core histone modifications . Moreover, linker histones are critical for the interaction of tNASP and HSPA2. We previously reported  that in mouse spermatogenic cells tNASP in the presence of CDC2 requires H1 linker histones to significantly increase HSPA2 ATPase activity. Therefore, depletion of tNASP should result in lesser amounts of HSPA2 activity implying that the interaction of tNASP and HSPA2 may be an important factor in the differential response of cancer cell lines to the depletion of tNASP. All three cell types in this study showed a decrease in HSPA2 protein levels (Figure 2) and the ATPase activity of HSPA2 was significantly increased in the presence of tNASP, but not sNASP (Figure 7).
HSPA2 activity was previously reported as a necessary chaperone for formation of an active CDC2-cyclin B1 complex in pachytene spermatocytes as a condition for successful completion of the G2/M transition . HSPA2 is not only essential for spermatogenesis , but is required for tumor cell growth and survival . HSPA2 depletion resulted in a senescence-like condition, arrest in the G1 phase of the cell cycle and up or down regulation of genes such as MIC-1 and p21 . Interestingly HSPA2 is required for survival of cancer cells , while non-tumorigenic cells (mammary MCF-10A, HBL-100, and prostate PNT1A) displayed no changes in survival after depletion of HSPA2. This selective effect is similar to our observation that although PWR-1E cells lost HSPA2 protein their survival was not affected.
Based on our data we conclude that the effect of tNASP depletion could be signaled through at least two different pathways: a loss of HSPA2 activity and a shortage of linker or core histones. Either of these pathways might lead to inhibited proliferation and apoptosis. The data presented here demonstrate that tNASP is required for the survival of prostate cancer PC-3 cells and its depletion results in anti-proliferative and pro-apoptotic activity. Targeting tNASP expression could lead to a new approach for cancer treatment.
List of abbreviations
The abbreviation used are
testis specific linker histone
nuclear autoantigenic sperm protein
testis/embryo form of nuclear autoantigenic sperm protein
somatic/embryo form of nuclear autoantigenic sperm protein
chromatin assembly factor
histone cell cycle regulation defective homolog A
heat shock protein A2
linker histone a
bovine serum albumin
phosphate buffered saline.
This study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institutes of Health through cooperative agreement U54 (HD35041) as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research.
The authors thank Professor Frank French from UNC Laboratories for Reproductive Biology for critical discussions and Dr. Ramiro Diz from UNC Department of Microbiology and Immunology for help with preparation and analysis of samples in the cell proliferation assay.
- Osakabe A, Tachiwana H, Matsunaga T, Shiga T, Nozawa RS, Obuse C, Kurumizaka H: Nucleosome formation activity of human somatic nuclear autoantigenic sperm protein (sNASP). J Biol Chem. 2010, 285 (16): 11913-11921. 10.1074/jbc.M109.083238.PubMed CentralView ArticlePubMedGoogle Scholar
- Richardson RT, Batova IN, Widgren EE, Zheng LX, Whitfield M, Marzluff WF, O'Rand MG: Characterization of the histone H1-binding protein, NASP, as a cell cycle-regulated somatic protein. J Biol Chem. 2000, 275 (39): 30378-30386. 10.1074/jbc.M003781200.View ArticlePubMedGoogle Scholar
- Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y: Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell. 2004, 116 (1): 51-61. 10.1016/S0092-8674(03)01064-X.View ArticlePubMedGoogle Scholar
- Wang H, Walsh STR, Parthun MR: Expanded binding specificity of the human histone chaperone NASP. Nucleic Acids Res. 2008, 36 (18): 5763-5772. 10.1093/nar/gkn574.PubMed CentralView ArticlePubMedGoogle Scholar
- Finn RM, Browne K, Hodgson KC, Ausio J: sNASP, a histone H1-specific eukaryotic chaperone dimer that facilitates chromatin assembly. Biophys J. 2008, 95 (3): 1314-1325. 10.1529/biophysj.108.130021.PubMed CentralView ArticlePubMedGoogle Scholar
- Welch J, O'Rand M: Characterization of a sperm-specific nuclear autoantigenic protein. II. Expression and localization in the testis. Biol Reprod. 1990, 43 (4): 569-578. 10.1095/biolreprod43.4.569.View ArticlePubMedGoogle Scholar
- Kleinschmidt J, Fortkamp E, Krohne G, Zentgraf H, Franke W: Co-existence of two different types of soluble histone complexes in nuclei of Xenopus laevis oocytes. J Biol Chem. 1985, 260 (2): 1166-1176.PubMedGoogle Scholar
- Kleinschmidt JA, Seiter A: Identification of domains involved in nuclear uptake and histone binding of protein N1 of Xenopus laevis. EMBO J. 1988, 7 (6): 1605-1614.PubMed CentralPubMedGoogle Scholar
- Alekseev OM, Bencic DC, Richardson RT, Widgren EE, O'Rand MG: Overexpression of the linker histone-binding protein tNASP affects progression through the cell cycle. J Biol Chem. 2003, 278 (10): 8846-8852. 10.1074/jbc.M210352200.View ArticlePubMedGoogle Scholar
- Alekseev OM, Richardson RT, Alekseev O, O'Rand MG: Analysis of gene expression profiles in HeLa cells in response to overexpression or siRNA-mediated depletion of NASP. Reprod Biol Endocrinol. 2009, 7 (1): 45-10.1186/1477-7827-7-45.PubMed CentralView ArticlePubMedGoogle Scholar
- Richardson RT, Alekseev OM, Grossman G, Widgren EE, Thresher R, Wagner EJ, Sullivan KD, Marzluff WF, O'Rand MG: Nuclear Autoantigenic Sperm Protein (NASP), a linker histone chaperone that is required for cell proliferation. J Biol Chem. 2006, 281 (30): 21526-21534. 10.1074/jbc.M603816200.View ArticlePubMedGoogle Scholar
- Sun Y, Li H, Liu Y, Mattson MP, Rao MS, Zhan M: Evolutionarily conserved transcriptional co-expression guiding embryonic stem cell differentiation. PLoS ONE. 2008, 3 (10): e3406-10.1371/journal.pone.0003406.PubMed CentralView ArticlePubMedGoogle Scholar
- Alekseev OM, Richardson RT, O'Rand MG: Linker histones stimulate HSPA2 ATPase activity through NASP binding and inhibit CDC2/cyclin B1 complex formation during meiosis in the mouse. Biol Reprod. 2009, 81 (4): 739-748. 10.1095/biolreprod.109.076497.PubMed CentralView ArticlePubMedGoogle Scholar
- Nakatani Y, Ray-Gallet D, Quivy J, Tagami H, Almouzni G: Two distinct nucleosome assembly pathways: dependent or independent of DNA synthesis promoted by histone H3.1 and H3.3 complexes. Cold Spring Harb Symp Quant Biol. 2004, 69: 273-280. 10.1101/sqb.2004.69.273.View ArticlePubMedGoogle Scholar
- Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007, 316 (5828): 1160-1166. 10.1126/science.1140321.View ArticlePubMedGoogle Scholar
- Chatterjee M, Mohapatra S, Ionan A, Bawa G, Ali-Fehmi R, Wang X, Nowak J, Ye B, Nahhas FA, Lu K, Witkin SS, Fishman D, Munkarah A, Morris R, Levin NK, Shirley NN, Tromp G, Abrams J, Draghici S, Tainsky MA: Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006, 66 (2): 1181-1190. 10.1158/0008-5472.CAN-04-2962.PubMed CentralView ArticlePubMedGoogle Scholar
- Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406 (6797): 747-752. 10.1038/35021093.View ArticlePubMedGoogle Scholar
- van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415 (6871): 530-536.View ArticleGoogle Scholar
- Martin KJ, Patrick DR, Bissell MJ, Fournier MV: Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets. PLoS ONE. 2008, 3 (8): e2994-10.1371/journal.pone.0002994.PubMed CentralView ArticlePubMedGoogle Scholar
- Maslikowski BM, Neel BD, Wu Y, Wang L, Rodrigues NA, Gillet G, Bedard PA: Cellular processes of v-Src transformation revealed by gene profiling of primary cells - implications for human cancer. BMC Cancer. 2010, 10: 41-10.1186/1471-2407-10-41.PubMed CentralView ArticlePubMedGoogle Scholar
- Amundson SA, Do KT, Vinikoor LC, Lee RA, Koch-Paiz CA, Ahn J, Reimers M, Chen Y, Scudiero DA, Weinstein JN, Trent JM, Bittner ML, Meltzer PS, Fornace AJ: Integrating global gene expression and radiation survival parameters across the 60 cell lines of the national cancer institute anticancer drug screen. Cancer Res. 2008, 68 (2): 415-424. 10.1158/0008-5472.CAN-07-2120.View ArticlePubMedGoogle Scholar
- Webber MM, Bello D, Kleinman HK, Wartinger DD, Williams DE, Rhim JS: Prostate specific antigen and androgen receptor induction and characterization of an immortalized adult human prostatic epithelial cell line. Carcinogenesis. 1996, 17 (8): 1641-1646. 10.1093/carcin/17.8.1641.View ArticlePubMedGoogle Scholar
- Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M: Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res. 2007, 67 (15): 7350-7357. 10.1158/0008-5472.CAN-07-0200.View ArticlePubMedGoogle Scholar
- Rödel F, Franz S, Sheriff A, Gaipl U, Heyder P, Hildebrandt G, Schultze-Mosgau S, Voll RE, Herrmann M: The CFSE distribution assay is a powerful technique for the analysis of radiation-induced cell death and survival on a single-sell level. Strahlenther Onkol. 2005, 181 (7): 456-462.View ArticlePubMedGoogle Scholar
- Broad Institute. [last accessed on April 12, 2011], [http://www.broadinstitute.org/rnai/trc/lib]
- Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, Carpenter AE, Foo SY, Stewart SA, Stockwell BR, Hacohen N, Hahn WC, Lander ES, Sabatini DM, Root DE: A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006, 124 (6): 1283-1298. 10.1016/j.cell.2006.01.040.View ArticlePubMedGoogle Scholar
- Addgene. [last accessed on April 12, 2011], [http://www.addgene.org/pgvec1]
- Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005, 307 (5712): 1098-1101. 10.1126/science.1106148.View ArticlePubMedGoogle Scholar
- PCR Array Data Analysis. [last accessed on April 12, 2011], [http://www.sabiosciences.com/pcr/arrayanalysis.php]
- Aherne W, Maloney A, Prodromou C, Rowlands MG, Hardcastle A, Boxall K, Clarke P, Walton MI, Pearl L, Workman P: Assays for HSP90 and inhibitors. Methods Mol Med. 2003, 85: 149-161.PubMedGoogle Scholar
- Webber MM, Bello D, Quader S: Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part I. Cell markers and immortalized nontumorigenic cell lines. Prostate. 1996, 29 (6): 386-394. 10.1002/(SICI)1097-0045(199612)29:6<386::AID-PROS7>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA. 1995, 92 (20): 9363-9367. 10.1073/pnas.92.20.9363.PubMed CentralView ArticlePubMedGoogle Scholar
- Ferrandina G, Ranelletti FO, Legge F, Lauriola L, Salutari V, Gessi M, Testa AC, Werner U, Navarra P, Tringali G, Battaglia A, Scambia G: Celecoxib modulates the expression of cyclooxygenase-2, ki67, apoptosis-related marker, and microvessel density in human cervical cancer: a pilot study. Clin Cancer Res. 2003, 9 (12): 4324-4331.PubMedGoogle Scholar
- Jeruc J, Vizjak A, Rozman B, Ferluga D: Immunohistochemical expression of activated caspase-3 as a marker of apoptosis in glomeruli of human lupus nephritis. Am J Kidney Dis. 2006, 48 (3): 410-418. 10.1053/j.ajkd.2006.05.019.View ArticlePubMedGoogle Scholar
- Rohde M, Daugaard M, Jensen MH, Helin K, Nylandsted J, Jaattela M: Members of the heat-shock protein 70 family promote cancer cell growth by distinct mechanisms. Genes Dev. 2005, 19 (5): 570-582. 10.1101/gad.305405.PubMed CentralView ArticlePubMedGoogle Scholar
- Nylandsted J, Brand K, Jaattela M: Heat shock protein 70 Is required for the survival of cancer cells. Ann N Y Acad Sci. 2000, 926: 122-125. 10.1111/j.1749-6632.2000.tb05605.x. Mechanisms of cell death II: the third annual conference of the international cell death societyView ArticlePubMedGoogle Scholar
- Lin Q, Sirotkin A, Skoultchi AI: Normal spermatogenesis in mice lacking the testis-specific linker histone H1t. Mol Cell Biol. 2000, 20 (6): 2122-2128. 10.1128/MCB.20.6.2122-2128.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Bénard J, Douc-Rasy S, Ahomadegbe JC: TP53 family members and human cancers. Hum Mutat. 2003, 21 (3): 182-191.View ArticlePubMedGoogle Scholar
- Post SM, Quintas-Cardama A, Terzian T, Smith C, Eischen CM, Lozano G: p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis. Oncogene. 2010, 29 (9): 1260-1269. 10.1038/onc.2009.423.PubMed CentralView ArticlePubMedGoogle Scholar
- Oh TJ, Kim CJ, Woo SK, Kim TS, Jeong DJ, Kim MS, Lee S, Cho HS, An S: Development and clinical evaluation of a highly sensitive DNA microarray for detection and genotyping of human papillomaviruses. J Clin Microbiol. 2004, 42 (7): 3272-3280. 10.1128/JCM.42.7.3272-3280.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Hoppe-Seyler F, Butz K: Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol. 1993, 67 (6): 3111-3117.PubMed CentralPubMedGoogle Scholar
- Carroll AG, Voeller HJ, Sugars L, Gelmann EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate. 1993, 23 (2): 123-134. 10.1002/pros.2990230206.View ArticlePubMedGoogle Scholar
- Muhlbauer KR, Grone HJ, Ernst T, Grone E, Tschada R, Hergenhahn M, Hollstein M: Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br J Cancer. 2003, 89 (4): 687-690. 10.1038/sj.bjc.6601164.PubMed CentralView ArticlePubMedGoogle Scholar
- Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJY, Shridhar V, De Bartolomeis A, Esposito V, Giuliano MT, Steinberg SM, Levine AS, Giordano A, Pass HI: Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med. 1997, 3 (8): 908-912. 10.1038/nm0897-908.View ArticlePubMedGoogle Scholar
- Wade Harper J, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993, 75 (4): 805-816. 10.1016/0092-8674(93)90499-G.View ArticleGoogle Scholar
- Deng C, Zhang P, Wade Harper J, Elledge SJ, Leder P: Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell. 1995, 82 (4): 675-684. 10.1016/0092-8674(95)90039-X.View ArticlePubMedGoogle Scholar
- Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature. 1995, 377 (6549): 552-557. 10.1038/377552a0.View ArticlePubMedGoogle Scholar
- Gartel AL, Najmabadi F, Goufman E, Tyner AL: A role for E2F1 in Ras activation of p21(WAF1/CIP1) transcription. Oncogene. 2000, 19 (7): 961-964. 10.1038/sj.onc.1203411.View ArticlePubMedGoogle Scholar
- Abbas T, Dutta A: p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009, 9 (6): 400-414. 10.1038/nrc2657.PubMed CentralView ArticlePubMedGoogle Scholar
- Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene. 2001, 20 (19): 2390-2400. 10.1038/sj.onc.1204383.View ArticlePubMedGoogle Scholar
- Alekseev OM, Widgren EE, Richardson RT, O'Rand MG: Association of NASP with HSP90 in mouse spermatogenic cells: stimulation of ATPase activity and transport of linker histones into nuclei. J Biol Chem. 2005, 280 (4): 2904-2911. 10.1074/jbc.M410397200.View ArticlePubMedGoogle Scholar
- Sancho M, Diani E, Beato M, Jordan A: Depletion of human histone H1 variants uncovers specific roles in gene expression and cell growth. PLoS Genet. 2008, 4 (10): e1000227-10.1371/journal.pgen.1000227.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu Z, Sittman D, Brown D, Munshi R, Leno G: Histone H1 modulates DNA replication through multiple pathways in Xenopus egg extract. J Cell Sci. 1997, 110 (21): 2745-2758.PubMedGoogle Scholar
- Fan Y, Nikitina T, Zhao J, Fleury TJ, Bhattacharyya R, Bouhassira EE, Stein A, Woodcock CL, Skoultchi AI: Histone H1 depletion in mammals alters global chromatin structure but causes specific changes in gene regulation. Cell. 2005, 123 (7): 1199-1212. 10.1016/j.cell.2005.10.028.View ArticlePubMedGoogle Scholar
- Eddy E: Role of heat shock protein HSP70-2 in spermatogenesis. Rev Reprod. 1999, 4 (1): 23-30. 10.1530/ror.0.0040023.View ArticlePubMedGoogle Scholar
- Zhu D, Dix D, Eddy E: HSP70-2 is required for CDC2 kinase activity in meiosis I of mouse spermatocytes. Development. 1997, 124 (15): 3007-3014.PubMedGoogle Scholar
- Daugaard M, Jäättelä M, Rohde M: Hsp70-2 is required for tumor cell growth and survival. Cell Cycle. 2005, 4 (7): 877-880. 10.4161/cc.4.7.1838.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.